Introduction
Bacterial meningitis in The Netherlands is caused predominantly by Neisseria meningitidis and Streptococcus pneumoniae. The incidence of Haemophilus influenzae type b meningitis has decreased strongly as a result of vaccination against this bacterium during the last 3.5 years. 1 Although the prevalence of resistance of N. meningitidis and S. pneumoniae to penicillin, chloramphenicol, or cephalosporins in The Netherlands is low, 1 the resistance of these organisms to antibiotics commonly used in the treatment of meningitis is increasing globally. 2, 3 The prevalence of penicillin resistant N. meningitidis is low in The Netherlands, 1 the UK (3%) 4 andthe USA (4%). 5 The prevalence of such strains in Spain, however, is 20-50%. 6 Pneumococcal resistance to penicillin due to changes in its penicillin binding proteins was first reported in 1965. 3 The prevalence of such resistance was limited until an epidemic of highly resistant pneumococci occurred in South Africa in 1977. 3 Since then, resistance has developed worldwide and in some regions it occurs in a frequency of up to 70%. 7 Reports of reduced susceptibility of pneumococci to several antibiotics, including broad-spectrum cephalosporins, have also recently been published. 7 Therefore it is essential to investigate the bacterial susceptibility of meningitis isolates to other classes of antibiotics appropriate for the treatment of patients with meningitis. The carbapenem meropenem excels in in-vitro activity against a broad range of bacteria including penicillin resistant pneumococci, 8 is stable to the majority of -lactamases, and penetrates well into the CSF. Furthermore, meropenem seems to lack the potential of causing seizures as has been reported for imipenemcilastatin, a structurally related carbapenem. 9 We tested the in-vitro susceptibility to meropenem of 299 N. meningitidis and 157 S. pneumoniae strains isolated from patients with meningitis. 
Materials and methods

Bacterial
Susceptibility testing
For susceptibility testing the Etest was used.
10 The inoculation procedure was performed according to the NCCLS guidelines.
10 The inocula were prepared by suspending bacteria in phosphate-buffered saline to achieve a turbidity equivalent to a 0.5 McFarland standard. A sterile, cotton swab was dipped into the bacterial suspension and the entire surface of an agar plate was swabbed four times, resulting in a confluent lawn of growth. For meningococci chocolate Mueller-Hinton agar (Oxoid Ltd, Basingstoke, UK) was used and for pneumococci Mueller-Hinton 5% sheep blood agar (Oxoid Ltd). All plates were incubated at 35°C in 95% air and 5% CO 2 for 18-24 h. The MIC value was read where bacterial growth intersected the Etest strip. The MIC criteria used for the Etest were those used for microorganisms tested by dilution susceptibility test methods (NCCLS). 10 Criteria for susceptibility to penicillin and rifampicin for meningococcal isolates have been suggested elsewhere, 2, 4 and results for chloramphenicol and ceftriaxone were interpreted according to the strictest NCCLS criteria for other microorganisms. 10 For determination of the susceptibility category, the Etest results were rounded up to the nearest two-fold dilution value, as recommended by the manufacturer. The susceptibility of N. meningitidis to meropenem, penicillin, ceftriaxone, chloramphenicol, and rifampicin, and of S. pneumoniae to meropenem, penicillin, ceftriaxone, and chloramphenicol was tested.
Results
The penicillin, ceftriaxone, and chloramphenicol susceptibility data for N. meningitidis and S. pneumoniae, as well as the rifampicin susceptibility data for N. meningitidis, are shown in the Table 
Discussion
Meropenem appears to be a rational addition to the therapeutic options for the treatment of patients with bacterial meningitis. It is, in vitro, highly effective against N. meningitidis and S. pneumoniae isolates causing meningitis and has, in contrast to third-generation cephalosporins, activity against some of the more unusual pathogens causing meningitis, particularly Listeria monocytogenes.
9
Previously we reported the susceptibility of N. meningitidis, S. pneumoniae, and H. influenzae isolates from meningitis cases to various antimicrobials. 1 The frequency of resistance to penicillin, ceftriaxone, chloramphenicol, and rifampicin amongthese isolates is very low. The strains tested for meropenem have been included in this previous survey.
All tested N. meningitidis and S. pneumoniae strains were susceptible to meropenem, including thirteen N. meningitidis strains of intermediate resistance topenicillin, the N. meningitidis strain resistant to rifampicin, and the S. pneumoniae strain of intermediate resistance to penicillin. As meropenem may be especially useful in the management of meningitis caused by meningococcal and pneumococcal strains resistant to these antibiotics, ideally a larger number of resistant strains should have been tested for susceptibility to meropenem. However, in a recent report the MICs of meropenem for three pneumococcal strains of intermediate resistance (MIC values of penicillin 0.125-1 mg/L) and twelve penicillin resistant strains (MIC values of penicillin 2 mg/L) were low, with MICs of meropenem ranging from 0.015-0.5 mg/L. 8 Interestingly, in our study
MICs of meropenem for penicillin resistant isolates were somewhat higher than MICs of penicillin susceptible strains. We conclude that meropenem is, in vitro, highly active against N. meningitidis and S. pneumoniae isolates from CSF and may emerge as an effective antimicrobial treatment for patients with bacterial meningitis.
